Steven Charlton
Chief Scientific Officer OMass Therapeutics
Steven is CSO at OMass Therapeutics and Professor of Molecular Pharmacology and Drug Discovery in the School of Life Sciences at Nottingham University. Prior to joining OMass, he was co-founder and CSO at Excellerate Bioscience, a CRO providing specialist molecular pharmacology support to the pharmaceutical industry. Steven has over 25 years of biotech, academic and pharma drug discovery experience, most notably at Novartis where he was Director of the Molecular Pharmacology Unit in Respiratory Diseases. He is interested in all aspects of the quantitative assessment of drug-target interactions, with a particular interest in the kinetics of ligand binding and signalling.
Seminars
Thursday 30th April 2026
Harnessing Long Residence Time to Overcome Hormone Fluctuations in Advancing MC2R Antagonists Toward the Clinic
3:15 pm
- Optimizing a long-residence MC2R antagonist that maintains efficacy despite large hormone surges, benefiting patients where fast-off antagonists lose effect
- Building an HPA-axis systems biology and PBPK framework allowing confident prediction of human responses before first-in-human studies
- Recreating human-challenge paradigms in aligned in vivo models demonstrating clear advantages of long-residence compounds and benefiting clinical translation
